BIOMEDICINSKE CENTRUM SLOVENSKEJ AKADEMIE VIED, VEREJNA VYSKUMNA INSTITUCIA

Their core work

The Biomedical Research Center of the Slovak Academy of Sciences is Slovakia's leading biomedical research institute, working across virology, oncology, and neuroscience. They maintain and distribute reference virus collections as part of the European Virus Archive, providing standardized biological materials to labs across Europe. They also develop microfluidic diagnostic tools for early cancer detection — particularly gastrointestinal cancers — and study tick-borne virus transmission mechanisms. Beyond bench research, they actively work to close the R&I performance gap between Central-Eastern and Western European life science institutions through institutional reform initiatives.

What they specialise in

How they've shifted over time

Their early H2020 work (2015–2018) centered on building institutional foundations — joining the European Virus Archive, participating in a Centre of Excellence for advanced materials (CEMEA), and addressing the R&I divide through Alliance4Life. From 2019 onward, they shifted toward more focused scientific leadership: coordinating their own projects on cancer diagnostics (VISION) and tick-borne virology (TVISTOFF), while continuing virus archive and capacity-building work. The trajectory shows a clear move from infrastructure participant to independent research leader in specific biomedical niches.

Moving from supporting roles in broad infrastructure projects toward coordinating targeted biomedical research, particularly in diagnostics and vector-borne diseases — expect them to seek partnerships where they lead the science.

How they like to work

Predominantly a consortium partner (6 of 9 projects), but with growing coordinator ambitions — both their coordinated projects came in 2019–2023, signaling increased confidence and capacity. With 105 unique partners across 37 countries, they are well-networked across Europe and not locked into a small circle. They are comfortable in both large research infrastructures (EVAg had dozens of partners) and smaller focused teams, making them a flexible collaborator.

Extensive European network spanning 105 partners in 37 countries, reflecting their involvement in large pan-European infrastructures like the European Virus Archive and VACCELERATE. Particularly well-connected to Central and Eastern European life science institutions through Alliance4Life and A4L_ACTIONS.

What sets them apart

They sit at a rare intersection: deep virology expertise (virus archives, tick-borne pathogens) combined with cancer diagnostics and a strong network in Central-Eastern European research reform. For consortium builders, they offer both scientific depth in biomedical research and a credible Widening country partner with genuine research capacity — not just a flag-of-convenience participant. Their dual role as virus archive contributor and emerging coordinator makes them particularly valuable for infectious disease or diagnostic-focused proposals.

Highlights from their portfolio

• EVA-GLOBAL
  Their largest funded project (€369K), continuing as a key node in Europe's reference virus collection infrastructure — directly relevant to pandemic preparedness.
• VISION
  Their first coordinated RIA project, developing microfluidic circulating tumor cell detection for gastrointestinal cancer — shows independent research leadership.
• TVISTOFF
  MSCA Individual Fellowship they coordinated, studying tick-borne encephalitis virus transmission through reverse genetics — demonstrates niche expertise in vector-borne diseases.